PYPD
PolyPid Ltd. Ordinary Shares
Prix en Temps Réel
Graphique des Prix
Métriques Clés
Métriques de Marché
Ouverture
$3.460
Haut
$3.460
Bas
$3.460
Volume
0.25M
Fondamentaux de l'Entreprise
Statistiques de Trading
Actualités Connexes
HC Wainwright & Co. Maintains Buy on PolyPid, Raises Price Target to $13
HC Wainwright & Co. analyst Brandon Folkes maintains PolyPid with a Buy and raises the price target from $11 to $13.
BriefCast Publishes Transcript: PolyPid Ltd. SHIELD II Phase 3 Trial Topline Results Call Transcript
In a call hosted today, June 9, 2025, PolyPid Ltd. unveiled highly successful topline results from its SHIELD II Phase 3 trial of D-PLEX100 for preventing surgical site infections (SSIs) in abdominal colorectal surgery
PolyPid Announces Positive Topline Results from Phase 3 SHIELD II Trial: D-PLEX₁₀₀ Demonstrated Significant Reduction in Surgical Site Infections and Successfully Met Primary and All Key Secondary Endpoints
D-PLEX100 successfully met the primary efficacy endpoint, with statistically significant results (p<0.005) in 798 patients with large abdominal surgery incisions.The trial successfully met all key secondary efficacy
PolyPid to Host Conference Call and Webcast to Discuss D-PLEX₁₀₀ SHIELD II Phase 3 Trial Topline Results on Monday, June 9, 2025
PETACH TIKVA, Israel, June 06, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD), ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will host a
Roth Capital Initiates Coverage On PolyPid with Buy Rating, Announces Price Target of $9
Roth Capital analyst Boobalan Pachaiyappan initiates coverage on PolyPid with a Buy rating and announces Price Target of $9.
Actions Connexes
Restez Informé
Configurez des alertes de prix, recevez des mises à jour d'analyses IA et des actualités de marché en temps réel.